Source: AFP
Security & Justice
Israel Army Says Hit Over 100 'Terror Targets' in Lebanon in Past Day
The Israeli military on Wednesday said it struck more than 100 "terror targets" in Lebanon over the past day and had "eliminated" two Hezbollah commanders at the weekend.
Wednesday, November 20, 2024
Israeli Strikes Kill Four Lebanese Soldiers in Two Days, Army Reports
Israeli Strikes Kill Four Lebanese Soldiers in Two Days, Army Reports
Wednesday, November 20, 2024
Opinion
Flying Above the Bombs, a Lebanese Airline Becomes an Unlikely National Hero
It used to be like almost any other national carrier, fielding gripes about flight delays, ticket prices and bad food.
Wednesday, November 20, 2024
Berri's Exclusive Control Over Ceasefire Talks: A Threat to National Interests?
As U.S. envoy Amos Hochstein continues his shuttle diplomacy between Tel Aviv and Beirut, aiming to broker a ceasefire agreement between Hezbollah and Israel, Lebanese political sources are increasingly calling for transparency in the negotiations. With the possibility of a ceasefire agreement looming, many are demanding that the Lebanese public be made aware of the terms being discussed behind closed doors, especially given the high stakes for Lebanon’s future and security.
Wednesday, November 20, 2024
Sports
Alcaraz Beats Rublev to Open ATP Finals Account
Carlos Alcaraz opened his account at the ATP Finals on Wednesday with an entertaining 6-3, 7-6 (10/8) win over Andrey Rublev which boosted his hopes of reaching the semifinals.
Wednesday, November 13, 2024
Ecuador's Angulo, 22, Dies a Month After Car Crash
Ecuador international Marco Angulo has died at the age of 22 just over a month after being seriously injured in a car crash, his club has announced.
Tuesday, November 12, 2024
Thursday 24 March 2022 11:48:27
Moderna Says Infant COVID-19 Vaccine Succeeded in Trial
US biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its COVID-19 vaccine in children aged six months to six years after the two-shot regimen was found to be safe and produced a strong immune response.
Specifically, two doses of 25 micrograms given to this age group generated similar levels of antibodies to two doses of 100 micrograms given to young people aged 18-25, indicating there would be similar levels of protection.
Based on the data, Moderna said it would submit authorization requests to the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and other global regulators in the coming weeks.
The results “are good news for parents of children under six years of age,” said CEO Stephane Bancel in a statement.
“We now have clinical data on the performance of our vaccine from infants six months of age through older adults.”
The company did however find relatively low vaccine efficacy against infection, with its trial taking place during the omicron wave.
Vaccine efficacy in children six months to two years was 43.7 percent, and vaccine efficacy was 37.5 percent in the two to under six years age group.
Moderna said this was consistent with what had been observed among adults and the company was evaluating a third dose to lift efficacy levels.
The trial comprised 11,700 pediatric volunteers in the United States and Canada, including 4,200 aged two to six years and 2,500 aged six to two months.
The company added that, after consulting with the FDA, it is also applying to be authorized among children six to 11 for two-doses of 50 micrograms, and updating its application for authorization in kids aged 12 through 17.
The EMA and other regulators have already authorized the Moderna vaccine in these age groups.
Last month, the FDA postponed a meeting of a panel to consider the Pfizer-BioNTech COVID-19 vaccine for children younger than five, saying it required additional data on third doses. The companies said they expected that data to be ready by April.
